Medical Care
Global Microbiome Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
- Mar 27, 25
- ID: 162793
- Pages: 120
- Figures: 119
- Views: 72
The global Microbiome Therapeutics market size was US$ 173 million in 2024 and is forecast to a readjusted size of US$ 1609 million by 2031 with a CAGR of 38.1% during the forecast period 2025-2031.
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that"s 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%.
For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.
North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.
Market competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.
The global Microbiome Therapeutics market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen
By Type: (Dominant Segment vs High-Margin Innovation)
Upper GIT
Lower GIT
By Application: (Core Demand Driver vs Emerging Opportunity)
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Seres Therapeutics in Europe)
- Emerging Product Trends: Upper GIT adoption vs. Lower GIT premiumization
- Demand-Side Dynamics: C. difficile Infection (CDI) growth in China vs. Inflammatory Bowel Disease (IBD) potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Microbiome Therapeutics market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Lower GIT in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Inflammatory Bowel Disease (IBD) in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Microbiome Therapeutics value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that"s 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%.
For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.
North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.
Market competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.
The global Microbiome Therapeutics market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen
By Type: (Dominant Segment vs High-Margin Innovation)
Upper GIT
Lower GIT
By Application: (Core Demand Driver vs Emerging Opportunity)
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Seres Therapeutics in Europe)
- Emerging Product Trends: Upper GIT adoption vs. Lower GIT premiumization
- Demand-Side Dynamics: C. difficile Infection (CDI) growth in China vs. Inflammatory Bowel Disease (IBD) potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Microbiome Therapeutics market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Lower GIT in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Inflammatory Bowel Disease (IBD) in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Microbiome Therapeutics value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Upper GIT
1.2.3 Lower GIT
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 C. difficile Infection (CDI)
1.3.3 Inflammatory Bowel Disease (IBD)
1.3.4 Orphan Drug
1.3.5 Immuno-oncology
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Microbiome Therapeutics Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Microbiome Therapeutics Revenue Market Share by Region (2020-2025)
2.4 Global Microbiome Therapeutics Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Microbiome Therapeutics Market Size and Prospective (2020-2031)
2.5.2 Europe Microbiome Therapeutics Market Size and Prospective (2020-2031)
2.5.3 China Microbiome Therapeutics Market Size and Prospective (2020-2031)
2.5.4 Japan Microbiome Therapeutics Market Size and Prospective (2020-2031)
2.5.5 Southeast Asia Microbiome Therapeutics Market Size and Prospective (2020-2031)
2.5.6 India Microbiome Therapeutics Market Size and Prospective (2020-2031)
2.5.7 Central & South America Microbiome Therapeutics Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Microbiome Therapeutics Historic Market Size by Type (2020-2025)
3.2 Global Microbiome Therapeutics Forecasted Market Size by Type (2026-2031)
3.3 Different Types Microbiome Therapeutics Representative Players
4 Breakdown Data by Application
4.1 Global Microbiome Therapeutics Historic Market Size by Application (2020-2025)
4.2 Global Microbiome Therapeutics Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Microbiome Therapeutics Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Microbiome Therapeutics Players by Revenue (2020-2025)
5.1.2 Global Microbiome Therapeutics Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Microbiome Therapeutics Revenue
5.4 Global Microbiome Therapeutics Market Concentration Analysis
5.4.1 Global Microbiome Therapeutics Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Microbiome Therapeutics Revenue in 2024
5.5 Global Key Players of Microbiome Therapeutics Head office and Area Served
5.6 Global Key Players of Microbiome Therapeutics, Product and Application
5.7 Global Key Players of Microbiome Therapeutics, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Microbiome Therapeutics Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Microbiome Therapeutics Market Size by Type (2020-2025)
6.1.2.2 North America Microbiome Therapeutics Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Microbiome Therapeutics Market Size by Application (2020-2025)
6.1.3.2 North America Microbiome Therapeutics Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Microbiome Therapeutics Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Microbiome Therapeutics Market Size by Type (2020-2025)
6.2.2.2 Europe Microbiome Therapeutics Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Microbiome Therapeutics Market Size by Application (2020-2025)
6.2.3.2 Europe Microbiome Therapeutics Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Microbiome Therapeutics Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Microbiome Therapeutics Market Size by Type (2020-2025)
6.3.2.2 China Microbiome Therapeutics Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China Microbiome Therapeutics Market Size by Application (2020-2025)
6.3.3.2 China Microbiome Therapeutics Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Microbiome Therapeutics Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Microbiome Therapeutics Market Size by Type (2020-2025)
6.4.2.2 Japan Microbiome Therapeutics Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Microbiome Therapeutics Market Size by Application (2020-2025)
6.4.3.2 Japan Microbiome Therapeutics Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
6.5 Southeast Asia Market: Players, Segments and Downstream
6.5.1 Southeast Asia Microbiome Therapeutics Revenue by Company (2020-2025)
6.5.2 Southeast Asia Market Size by Type
6.5.2.1 Southeast Asia Microbiome Therapeutics Market Size by Type (2020-2025)
6.5.2.2 Southeast Asia Microbiome Therapeutics Market Share by Type (2020-2025)
6.5.3 Southeast Asia Market Size by Application
6.5.3.1 Southeast Asia Microbiome Therapeutics Market Size by Application (2020-2025)
6.5.3.2 Southeast Asia Microbiome Therapeutics Market Share by Application (2020-2025)
6.5.4 Southeast Asia Market Trend and Opportunities
6.6 India Market: Players, Segments and Downstream
6.6.1 India Microbiome Therapeutics Revenue by Company (2020-2025)
6.6.2 India Market Size by Type
6.6.2.1 India Microbiome Therapeutics Market Size by Type (2020-2025)
6.6.2.2 India Microbiome Therapeutics Market Share by Type (2020-2025)
6.6.3 India Market Size by Application
6.6.3.1 India Microbiome Therapeutics Market Size by Application (2020-2025)
6.6.3.2 India Microbiome Therapeutics Market Share by Application (2020-2025)
6.6.4 India Market Trend and Opportunities
7 Key Players Profiles
7.1 Seres Therapeutics
7.1.1 Seres Therapeutics Company Details
7.1.2 Seres Therapeutics Business Overview
7.1.3 Seres Therapeutics Microbiome Therapeutics Introduction
7.1.4 Seres Therapeutics Revenue in Microbiome Therapeutics Business (2020-2025)
7.1.5 Seres Therapeutics Recent Development
7.2 Assembly Biosciences
7.2.1 Assembly Biosciences Company Details
7.2.2 Assembly Biosciences Business Overview
7.2.3 Assembly Biosciences Microbiome Therapeutics Introduction
7.2.4 Assembly Biosciences Revenue in Microbiome Therapeutics Business (2020-2025)
7.2.5 Assembly Biosciences Recent Development
7.3 Synthetic Biologics
7.3.1 Synthetic Biologics Company Details
7.3.2 Synthetic Biologics Business Overview
7.3.3 Synthetic Biologics Microbiome Therapeutics Introduction
7.3.4 Synthetic Biologics Revenue in Microbiome Therapeutics Business (2020-2025)
7.3.5 Synthetic Biologics Recent Development
7.4 Interxon
7.4.1 Interxon Company Details
7.4.2 Interxon Business Overview
7.4.3 Interxon Microbiome Therapeutics Introduction
7.4.4 Interxon Revenue in Microbiome Therapeutics Business (2020-2025)
7.4.5 Interxon Recent Development
7.5 PureTech
7.5.1 PureTech Company Details
7.5.2 PureTech Business Overview
7.5.3 PureTech Microbiome Therapeutics Introduction
7.5.4 PureTech Revenue in Microbiome Therapeutics Business (2020-2025)
7.5.5 PureTech Recent Development
7.6 Synlogic
7.6.1 Synlogic Company Details
7.6.2 Synlogic Business Overview
7.6.3 Synlogic Microbiome Therapeutics Introduction
7.6.4 Synlogic Revenue in Microbiome Therapeutics Business (2020-2025)
7.6.5 Synlogic Recent Development
7.7 Enterome BioScience
7.7.1 Enterome BioScience Company Details
7.7.2 Enterome BioScience Business Overview
7.7.3 Enterome BioScience Microbiome Therapeutics Introduction
7.7.4 Enterome BioScience Revenue in Microbiome Therapeutics Business (2020-2025)
7.7.5 Enterome BioScience Recent Development
7.8 4D Pharma
7.8.1 4D Pharma Company Details
7.8.2 4D Pharma Business Overview
7.8.3 4D Pharma Microbiome Therapeutics Introduction
7.8.4 4D Pharma Revenue in Microbiome Therapeutics Business (2020-2025)
7.8.5 4D Pharma Recent Development
7.9 Second Genome
7.9.1 Second Genome Company Details
7.9.2 Second Genome Business Overview
7.9.3 Second Genome Microbiome Therapeutics Introduction
7.9.4 Second Genome Revenue in Microbiome Therapeutics Business (2020-2025)
7.9.5 Second Genome Recent Development
7.10 AOBiome
7.10.1 AOBiome Company Details
7.10.2 AOBiome Business Overview
7.10.3 AOBiome Microbiome Therapeutics Introduction
7.10.4 AOBiome Revenue in Microbiome Therapeutics Business (2020-2025)
7.10.5 AOBiome Recent Development
7.11 C3 Jian
7.11.1 C3 Jian Company Details
7.11.2 C3 Jian Business Overview
7.11.3 C3 Jian Microbiome Therapeutics Introduction
7.11.4 C3 Jian Revenue in Microbiome Therapeutics Business (2020-2025)
7.11.5 C3 Jian Recent Development
7.12 Rebiotix
7.12.1 Rebiotix Company Details
7.12.2 Rebiotix Business Overview
7.12.3 Rebiotix Microbiome Therapeutics Introduction
7.12.4 Rebiotix Revenue in Microbiome Therapeutics Business (2020-2025)
7.12.5 Rebiotix Recent Development
7.13 MicroBiome Therapeutics LLC
7.13.1 MicroBiome Therapeutics LLC Company Details
7.13.2 MicroBiome Therapeutics LLC Business Overview
7.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Introduction
7.13.4 MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2020-2025)
7.13.5 MicroBiome Therapeutics LLC Recent Development
7.14 Metabiomics
7.14.1 Metabiomics Company Details
7.14.2 Metabiomics Business Overview
7.14.3 Metabiomics Microbiome Therapeutics Introduction
7.14.4 Metabiomics Revenue in Microbiome Therapeutics Business (2020-2025)
7.14.5 Metabiomics Recent Development
7.15 Ritter Pharmaceuticals
7.15.1 Ritter Pharmaceuticals Company Details
7.15.2 Ritter Pharmaceuticals Business Overview
7.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Introduction
7.15.4 Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2020-2025)
7.15.5 Ritter Pharmaceuticals Recent Development
7.16 Symberix
7.16.1 Symberix Company Details
7.16.2 Symberix Business Overview
7.16.3 Symberix Microbiome Therapeutics Introduction
7.16.4 Symberix Revenue in Microbiome Therapeutics Business (2020-2025)
7.16.5 Symberix Recent Development
7.17 OpenBiome
7.17.1 OpenBiome Company Details
7.17.2 OpenBiome Business Overview
7.17.3 OpenBiome Microbiome Therapeutics Introduction
7.17.4 OpenBiome Revenue in Microbiome Therapeutics Business (2020-2025)
7.17.5 OpenBiome Recent Development
7.18 Azitra
7.18.1 Azitra Company Details
7.18.2 Azitra Business Overview
7.18.3 Azitra Microbiome Therapeutics Introduction
7.18.4 Azitra Revenue in Microbiome Therapeutics Business (2020-2025)
7.18.5 Azitra Recent Development
7.19 Symbiotix Biotherapies
7.19.1 Symbiotix Biotherapies Company Details
7.19.2 Symbiotix Biotherapies Business Overview
7.19.3 Symbiotix Biotherapies Microbiome Therapeutics Introduction
7.19.4 Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2020-2025)
7.19.5 Symbiotix Biotherapies Recent Development
7.20 Osel
7.20.1 Osel Company Details
7.20.2 Osel Business Overview
7.20.3 Osel Microbiome Therapeutics Introduction
7.20.4 Osel Revenue in Microbiome Therapeutics Business (2020-2025)
7.20.5 Osel Recent Development
7.21 Metabogen
7.21.1 Metabogen Company Details
7.21.2 Metabogen Business Overview
7.21.3 Metabogen Microbiome Therapeutics Introduction
7.21.4 Metabogen Revenue in Microbiome Therapeutics Business (2020-2025)
7.21.5 Metabogen Recent Development
8 Microbiome Therapeutics Market Dynamics
8.1 Microbiome Therapeutics Industry Trends
8.2 Microbiome Therapeutics Market Drivers
8.3 Microbiome Therapeutics Market Challenges
8.4 Microbiome Therapeutics Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Upper GIT
1.2.3 Lower GIT
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 C. difficile Infection (CDI)
1.3.3 Inflammatory Bowel Disease (IBD)
1.3.4 Orphan Drug
1.3.5 Immuno-oncology
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Microbiome Therapeutics Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Microbiome Therapeutics Revenue Market Share by Region (2020-2025)
2.4 Global Microbiome Therapeutics Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Microbiome Therapeutics Market Size and Prospective (2020-2031)
2.5.2 Europe Microbiome Therapeutics Market Size and Prospective (2020-2031)
2.5.3 China Microbiome Therapeutics Market Size and Prospective (2020-2031)
2.5.4 Japan Microbiome Therapeutics Market Size and Prospective (2020-2031)
2.5.5 Southeast Asia Microbiome Therapeutics Market Size and Prospective (2020-2031)
2.5.6 India Microbiome Therapeutics Market Size and Prospective (2020-2031)
2.5.7 Central & South America Microbiome Therapeutics Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Microbiome Therapeutics Historic Market Size by Type (2020-2025)
3.2 Global Microbiome Therapeutics Forecasted Market Size by Type (2026-2031)
3.3 Different Types Microbiome Therapeutics Representative Players
4 Breakdown Data by Application
4.1 Global Microbiome Therapeutics Historic Market Size by Application (2020-2025)
4.2 Global Microbiome Therapeutics Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Microbiome Therapeutics Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Microbiome Therapeutics Players by Revenue (2020-2025)
5.1.2 Global Microbiome Therapeutics Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Microbiome Therapeutics Revenue
5.4 Global Microbiome Therapeutics Market Concentration Analysis
5.4.1 Global Microbiome Therapeutics Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Microbiome Therapeutics Revenue in 2024
5.5 Global Key Players of Microbiome Therapeutics Head office and Area Served
5.6 Global Key Players of Microbiome Therapeutics, Product and Application
5.7 Global Key Players of Microbiome Therapeutics, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Microbiome Therapeutics Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Microbiome Therapeutics Market Size by Type (2020-2025)
6.1.2.2 North America Microbiome Therapeutics Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Microbiome Therapeutics Market Size by Application (2020-2025)
6.1.3.2 North America Microbiome Therapeutics Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Microbiome Therapeutics Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Microbiome Therapeutics Market Size by Type (2020-2025)
6.2.2.2 Europe Microbiome Therapeutics Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Microbiome Therapeutics Market Size by Application (2020-2025)
6.2.3.2 Europe Microbiome Therapeutics Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Microbiome Therapeutics Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Microbiome Therapeutics Market Size by Type (2020-2025)
6.3.2.2 China Microbiome Therapeutics Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China Microbiome Therapeutics Market Size by Application (2020-2025)
6.3.3.2 China Microbiome Therapeutics Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Microbiome Therapeutics Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Microbiome Therapeutics Market Size by Type (2020-2025)
6.4.2.2 Japan Microbiome Therapeutics Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Microbiome Therapeutics Market Size by Application (2020-2025)
6.4.3.2 Japan Microbiome Therapeutics Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
6.5 Southeast Asia Market: Players, Segments and Downstream
6.5.1 Southeast Asia Microbiome Therapeutics Revenue by Company (2020-2025)
6.5.2 Southeast Asia Market Size by Type
6.5.2.1 Southeast Asia Microbiome Therapeutics Market Size by Type (2020-2025)
6.5.2.2 Southeast Asia Microbiome Therapeutics Market Share by Type (2020-2025)
6.5.3 Southeast Asia Market Size by Application
6.5.3.1 Southeast Asia Microbiome Therapeutics Market Size by Application (2020-2025)
6.5.3.2 Southeast Asia Microbiome Therapeutics Market Share by Application (2020-2025)
6.5.4 Southeast Asia Market Trend and Opportunities
6.6 India Market: Players, Segments and Downstream
6.6.1 India Microbiome Therapeutics Revenue by Company (2020-2025)
6.6.2 India Market Size by Type
6.6.2.1 India Microbiome Therapeutics Market Size by Type (2020-2025)
6.6.2.2 India Microbiome Therapeutics Market Share by Type (2020-2025)
6.6.3 India Market Size by Application
6.6.3.1 India Microbiome Therapeutics Market Size by Application (2020-2025)
6.6.3.2 India Microbiome Therapeutics Market Share by Application (2020-2025)
6.6.4 India Market Trend and Opportunities
7 Key Players Profiles
7.1 Seres Therapeutics
7.1.1 Seres Therapeutics Company Details
7.1.2 Seres Therapeutics Business Overview
7.1.3 Seres Therapeutics Microbiome Therapeutics Introduction
7.1.4 Seres Therapeutics Revenue in Microbiome Therapeutics Business (2020-2025)
7.1.5 Seres Therapeutics Recent Development
7.2 Assembly Biosciences
7.2.1 Assembly Biosciences Company Details
7.2.2 Assembly Biosciences Business Overview
7.2.3 Assembly Biosciences Microbiome Therapeutics Introduction
7.2.4 Assembly Biosciences Revenue in Microbiome Therapeutics Business (2020-2025)
7.2.5 Assembly Biosciences Recent Development
7.3 Synthetic Biologics
7.3.1 Synthetic Biologics Company Details
7.3.2 Synthetic Biologics Business Overview
7.3.3 Synthetic Biologics Microbiome Therapeutics Introduction
7.3.4 Synthetic Biologics Revenue in Microbiome Therapeutics Business (2020-2025)
7.3.5 Synthetic Biologics Recent Development
7.4 Interxon
7.4.1 Interxon Company Details
7.4.2 Interxon Business Overview
7.4.3 Interxon Microbiome Therapeutics Introduction
7.4.4 Interxon Revenue in Microbiome Therapeutics Business (2020-2025)
7.4.5 Interxon Recent Development
7.5 PureTech
7.5.1 PureTech Company Details
7.5.2 PureTech Business Overview
7.5.3 PureTech Microbiome Therapeutics Introduction
7.5.4 PureTech Revenue in Microbiome Therapeutics Business (2020-2025)
7.5.5 PureTech Recent Development
7.6 Synlogic
7.6.1 Synlogic Company Details
7.6.2 Synlogic Business Overview
7.6.3 Synlogic Microbiome Therapeutics Introduction
7.6.4 Synlogic Revenue in Microbiome Therapeutics Business (2020-2025)
7.6.5 Synlogic Recent Development
7.7 Enterome BioScience
7.7.1 Enterome BioScience Company Details
7.7.2 Enterome BioScience Business Overview
7.7.3 Enterome BioScience Microbiome Therapeutics Introduction
7.7.4 Enterome BioScience Revenue in Microbiome Therapeutics Business (2020-2025)
7.7.5 Enterome BioScience Recent Development
7.8 4D Pharma
7.8.1 4D Pharma Company Details
7.8.2 4D Pharma Business Overview
7.8.3 4D Pharma Microbiome Therapeutics Introduction
7.8.4 4D Pharma Revenue in Microbiome Therapeutics Business (2020-2025)
7.8.5 4D Pharma Recent Development
7.9 Second Genome
7.9.1 Second Genome Company Details
7.9.2 Second Genome Business Overview
7.9.3 Second Genome Microbiome Therapeutics Introduction
7.9.4 Second Genome Revenue in Microbiome Therapeutics Business (2020-2025)
7.9.5 Second Genome Recent Development
7.10 AOBiome
7.10.1 AOBiome Company Details
7.10.2 AOBiome Business Overview
7.10.3 AOBiome Microbiome Therapeutics Introduction
7.10.4 AOBiome Revenue in Microbiome Therapeutics Business (2020-2025)
7.10.5 AOBiome Recent Development
7.11 C3 Jian
7.11.1 C3 Jian Company Details
7.11.2 C3 Jian Business Overview
7.11.3 C3 Jian Microbiome Therapeutics Introduction
7.11.4 C3 Jian Revenue in Microbiome Therapeutics Business (2020-2025)
7.11.5 C3 Jian Recent Development
7.12 Rebiotix
7.12.1 Rebiotix Company Details
7.12.2 Rebiotix Business Overview
7.12.3 Rebiotix Microbiome Therapeutics Introduction
7.12.4 Rebiotix Revenue in Microbiome Therapeutics Business (2020-2025)
7.12.5 Rebiotix Recent Development
7.13 MicroBiome Therapeutics LLC
7.13.1 MicroBiome Therapeutics LLC Company Details
7.13.2 MicroBiome Therapeutics LLC Business Overview
7.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Introduction
7.13.4 MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2020-2025)
7.13.5 MicroBiome Therapeutics LLC Recent Development
7.14 Metabiomics
7.14.1 Metabiomics Company Details
7.14.2 Metabiomics Business Overview
7.14.3 Metabiomics Microbiome Therapeutics Introduction
7.14.4 Metabiomics Revenue in Microbiome Therapeutics Business (2020-2025)
7.14.5 Metabiomics Recent Development
7.15 Ritter Pharmaceuticals
7.15.1 Ritter Pharmaceuticals Company Details
7.15.2 Ritter Pharmaceuticals Business Overview
7.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Introduction
7.15.4 Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2020-2025)
7.15.5 Ritter Pharmaceuticals Recent Development
7.16 Symberix
7.16.1 Symberix Company Details
7.16.2 Symberix Business Overview
7.16.3 Symberix Microbiome Therapeutics Introduction
7.16.4 Symberix Revenue in Microbiome Therapeutics Business (2020-2025)
7.16.5 Symberix Recent Development
7.17 OpenBiome
7.17.1 OpenBiome Company Details
7.17.2 OpenBiome Business Overview
7.17.3 OpenBiome Microbiome Therapeutics Introduction
7.17.4 OpenBiome Revenue in Microbiome Therapeutics Business (2020-2025)
7.17.5 OpenBiome Recent Development
7.18 Azitra
7.18.1 Azitra Company Details
7.18.2 Azitra Business Overview
7.18.3 Azitra Microbiome Therapeutics Introduction
7.18.4 Azitra Revenue in Microbiome Therapeutics Business (2020-2025)
7.18.5 Azitra Recent Development
7.19 Symbiotix Biotherapies
7.19.1 Symbiotix Biotherapies Company Details
7.19.2 Symbiotix Biotherapies Business Overview
7.19.3 Symbiotix Biotherapies Microbiome Therapeutics Introduction
7.19.4 Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2020-2025)
7.19.5 Symbiotix Biotherapies Recent Development
7.20 Osel
7.20.1 Osel Company Details
7.20.2 Osel Business Overview
7.20.3 Osel Microbiome Therapeutics Introduction
7.20.4 Osel Revenue in Microbiome Therapeutics Business (2020-2025)
7.20.5 Osel Recent Development
7.21 Metabogen
7.21.1 Metabogen Company Details
7.21.2 Metabogen Business Overview
7.21.3 Metabogen Microbiome Therapeutics Introduction
7.21.4 Metabogen Revenue in Microbiome Therapeutics Business (2020-2025)
7.21.5 Metabogen Recent Development
8 Microbiome Therapeutics Market Dynamics
8.1 Microbiome Therapeutics Industry Trends
8.2 Microbiome Therapeutics Market Drivers
8.3 Microbiome Therapeutics Market Challenges
8.4 Microbiome Therapeutics Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Global Microbiome Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Microbiome Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Microbiome Therapeutics Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Microbiome Therapeutics Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Microbiome Therapeutics Revenue Share by Region (2020-2025)
Table 6. Global Microbiome Therapeutics Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Microbiome Therapeutics Revenue Share Forecast by Region (2026-2031)
Table 8. Global Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Microbiome Therapeutics Revenue Market Share by Type (2020-2025)
Table 10. Global Microbiome Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Microbiome Therapeutics Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Microbiome Therapeutics Revenue Market Share by Application (2020-2025)
Table 15. Global Microbiome Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Microbiome Therapeutics Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Microbiome Therapeutics Application
Table 18. Global Microbiome Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Microbiome Therapeutics Market Share by Players (2020-2025)
Table 20. Global Top Microbiome Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Therapeutics as of 2024)
Table 21. Ranking of Global Top Microbiome Therapeutics Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Microbiome Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Microbiome Therapeutics, Headquarters and Area Served
Table 24. Global Key Players of Microbiome Therapeutics, Product and Application
Table 25. Global Key Players of Microbiome Therapeutics, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
Table 29. North America Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
Table 33. Europe Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 35. China Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 36. China Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
Table 37. China Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 38. China Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 39. Japan Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
Table 41. Japan Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 43. Southeast Asia Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 44. Southeast Asia Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
Table 45. Southeast Asia Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 46. Southeast Asia Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 47. India Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 48. India Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
Table 49. India Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 50. India Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 51. Seres Therapeutics Company Details
Table 52. Seres Therapeutics Business Overview
Table 53. Seres Therapeutics Microbiome Therapeutics Product
Table 54. Seres Therapeutics Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 55. Seres Therapeutics Recent Development
Table 56. Assembly Biosciences Company Details
Table 57. Assembly Biosciences Business Overview
Table 58. Assembly Biosciences Microbiome Therapeutics Product
Table 59. Assembly Biosciences Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 60. Assembly Biosciences Recent Development
Table 61. Synthetic Biologics Company Details
Table 62. Synthetic Biologics Business Overview
Table 63. Synthetic Biologics Microbiome Therapeutics Product
Table 64. Synthetic Biologics Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 65. Synthetic Biologics Recent Development
Table 66. Interxon Company Details
Table 67. Interxon Business Overview
Table 68. Interxon Microbiome Therapeutics Product
Table 69. Interxon Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 70. Interxon Recent Development
Table 71. PureTech Company Details
Table 72. PureTech Business Overview
Table 73. PureTech Microbiome Therapeutics Product
Table 74. PureTech Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 75. PureTech Recent Development
Table 76. Synlogic Company Details
Table 77. Synlogic Business Overview
Table 78. Synlogic Microbiome Therapeutics Product
Table 79. Synlogic Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 80. Synlogic Recent Development
Table 81. Enterome BioScience Company Details
Table 82. Enterome BioScience Business Overview
Table 83. Enterome BioScience Microbiome Therapeutics Product
Table 84. Enterome BioScience Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 85. Enterome BioScience Recent Development
Table 86. 4D Pharma Company Details
Table 87. 4D Pharma Business Overview
Table 88. 4D Pharma Microbiome Therapeutics Product
Table 89. 4D Pharma Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 90. 4D Pharma Recent Development
Table 91. Second Genome Company Details
Table 92. Second Genome Business Overview
Table 93. Second Genome Microbiome Therapeutics Product
Table 94. Second Genome Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 95. Second Genome Recent Development
Table 96. AOBiome Company Details
Table 97. AOBiome Business Overview
Table 98. AOBiome Microbiome Therapeutics Product
Table 99. AOBiome Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 100. AOBiome Recent Development
Table 101. C3 Jian Company Details
Table 102. C3 Jian Business Overview
Table 103. C3 Jian Microbiome Therapeutics Product
Table 104. C3 Jian Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 105. C3 Jian Recent Development
Table 106. Rebiotix Company Details
Table 107. Rebiotix Business Overview
Table 108. Rebiotix Microbiome Therapeutics Product
Table 109. Rebiotix Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 110. Rebiotix Recent Development
Table 111. MicroBiome Therapeutics LLC Company Details
Table 112. MicroBiome Therapeutics LLC Business Overview
Table 113. MicroBiome Therapeutics LLC Microbiome Therapeutics Product
Table 114. MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 115. MicroBiome Therapeutics LLC Recent Development
Table 116. Metabiomics Company Details
Table 117. Metabiomics Business Overview
Table 118. Metabiomics Microbiome Therapeutics Product
Table 119. Metabiomics Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 120. Metabiomics Recent Development
Table 121. Ritter Pharmaceuticals Company Details
Table 122. Ritter Pharmaceuticals Business Overview
Table 123. Ritter Pharmaceuticals Microbiome Therapeutics Product
Table 124. Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 125. Ritter Pharmaceuticals Recent Development
Table 126. Symberix Company Details
Table 127. Symberix Business Overview
Table 128. Symberix Microbiome Therapeutics Product
Table 129. Symberix Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 130. Symberix Recent Development
Table 131. OpenBiome Company Details
Table 132. OpenBiome Business Overview
Table 133. OpenBiome Microbiome Therapeutics Product
Table 134. OpenBiome Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 135. OpenBiome Recent Development
Table 136. Azitra Company Details
Table 137. Azitra Business Overview
Table 138. Azitra Microbiome Therapeutics Product
Table 139. Azitra Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 140. Azitra Recent Development
Table 141. Symbiotix Biotherapies Company Details
Table 142. Symbiotix Biotherapies Business Overview
Table 143. Symbiotix Biotherapies Microbiome Therapeutics Product
Table 144. Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 145. Symbiotix Biotherapies Recent Development
Table 146. Osel Company Details
Table 147. Osel Business Overview
Table 148. Osel Microbiome Therapeutics Product
Table 149. Osel Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 150. Osel Recent Development
Table 151. Metabogen Company Details
Table 152. Metabogen Business Overview
Table 153. Metabogen Microbiome Therapeutics Product
Table 154. Metabogen Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 155. Metabogen Recent Development
Table 156. Microbiome Therapeutics Market Trends
Table 157. Microbiome Therapeutics Market Drivers
Table 158. Microbiome Therapeutics Market Challenges
Table 159. Microbiome Therapeutics Market Restraints
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
List of Figures
Figure 1. Microbiome Therapeutics Product Picture
Figure 2. Global Microbiome Therapeutics Market Share by Type: 2024 VS 2031
Figure 3. Upper GIT Features
Figure 4. Lower GIT Features
Figure 5. Global Microbiome Therapeutics Market Share by Application: 2024 VS 2031
Figure 6. C. difficile Infection (CDI)
Figure 7. Inflammatory Bowel Disease (IBD)
Figure 8. Orphan Drug
Figure 9. Immuno-oncology
Figure 10. Others
Figure 11. Microbiome Therapeutics Report Years Considered
Figure 12. Global Microbiome Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Microbiome Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Microbiome Therapeutics Revenue Market Share by Region: 2020 VS 2024
Figure 15. North America Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Europe Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. China Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. Japan Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 19. Southeast Asia Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. India Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 21. Central & South America Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. Global Microbiome Therapeutics Market Share by Players in 2024
Figure 23. Global Top Microbiome Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Therapeutics as of 2024)
Figure 24. The Top 10 and 5 Players Market Share by Microbiome Therapeutics Revenue in 2024
Figure 25. North America Microbiome Therapeutics Market Share by Type (2020-2025)
Figure 26. North America Microbiome Therapeutics Market Share by Application (2020-2025)
Figure 27. Europe Microbiome Therapeutics Market Share by Type (2020-2025)
Figure 28. Europe Microbiome Therapeutics Market Share by Application (2020-2025)
Figure 29. China Microbiome Therapeutics Market Share by Type (2020-2025)
Figure 30. China Microbiome Therapeutics Market Share by Application (2020-2025)
Figure 31. Japan Microbiome Therapeutics Market Share by Type (2020-2025)
Figure 32. Japan Microbiome Therapeutics Market Share by Application (2020-2025)
Figure 33. Southeast Asia Microbiome Therapeutics Market Share by Type (2020-2025)
Figure 34. Southeast Asia Microbiome Therapeutics Market Share by Application (2020-2025)
Figure 35. India Microbiome Therapeutics Market Share by Type (2020-2025)
Figure 36. India Microbiome Therapeutics Market Share by Application (2020-2025)
Figure 37. Seres Therapeutics Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 38. Assembly Biosciences Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 39. Synthetic Biologics Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 40. Interxon Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 41. PureTech Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 42. Synlogic Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 43. Enterome BioScience Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 44. 4D Pharma Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 45. Second Genome Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 46. AOBiome Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 47. C3 Jian Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 48. Rebiotix Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 49. MicroBiome Therapeutics LLC Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 50. Metabiomics Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 51. Ritter Pharmaceuticals Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 52. Symberix Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 53. OpenBiome Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 54. Azitra Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 55. Symbiotix Biotherapies Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 56. Osel Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 57. Metabogen Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Table 1. Global Microbiome Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Microbiome Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Microbiome Therapeutics Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Microbiome Therapeutics Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Microbiome Therapeutics Revenue Share by Region (2020-2025)
Table 6. Global Microbiome Therapeutics Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Microbiome Therapeutics Revenue Share Forecast by Region (2026-2031)
Table 8. Global Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Microbiome Therapeutics Revenue Market Share by Type (2020-2025)
Table 10. Global Microbiome Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Microbiome Therapeutics Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Microbiome Therapeutics Revenue Market Share by Application (2020-2025)
Table 15. Global Microbiome Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Microbiome Therapeutics Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Microbiome Therapeutics Application
Table 18. Global Microbiome Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Microbiome Therapeutics Market Share by Players (2020-2025)
Table 20. Global Top Microbiome Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Therapeutics as of 2024)
Table 21. Ranking of Global Top Microbiome Therapeutics Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Microbiome Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Microbiome Therapeutics, Headquarters and Area Served
Table 24. Global Key Players of Microbiome Therapeutics, Product and Application
Table 25. Global Key Players of Microbiome Therapeutics, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
Table 29. North America Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
Table 33. Europe Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 35. China Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 36. China Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
Table 37. China Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 38. China Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 39. Japan Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
Table 41. Japan Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 43. Southeast Asia Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 44. Southeast Asia Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
Table 45. Southeast Asia Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 46. Southeast Asia Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 47. India Microbiome Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 48. India Microbiome Therapeutics Revenue Market Share by Company (2020-2025)
Table 49. India Microbiome Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 50. India Microbiome Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 51. Seres Therapeutics Company Details
Table 52. Seres Therapeutics Business Overview
Table 53. Seres Therapeutics Microbiome Therapeutics Product
Table 54. Seres Therapeutics Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 55. Seres Therapeutics Recent Development
Table 56. Assembly Biosciences Company Details
Table 57. Assembly Biosciences Business Overview
Table 58. Assembly Biosciences Microbiome Therapeutics Product
Table 59. Assembly Biosciences Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 60. Assembly Biosciences Recent Development
Table 61. Synthetic Biologics Company Details
Table 62. Synthetic Biologics Business Overview
Table 63. Synthetic Biologics Microbiome Therapeutics Product
Table 64. Synthetic Biologics Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 65. Synthetic Biologics Recent Development
Table 66. Interxon Company Details
Table 67. Interxon Business Overview
Table 68. Interxon Microbiome Therapeutics Product
Table 69. Interxon Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 70. Interxon Recent Development
Table 71. PureTech Company Details
Table 72. PureTech Business Overview
Table 73. PureTech Microbiome Therapeutics Product
Table 74. PureTech Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 75. PureTech Recent Development
Table 76. Synlogic Company Details
Table 77. Synlogic Business Overview
Table 78. Synlogic Microbiome Therapeutics Product
Table 79. Synlogic Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 80. Synlogic Recent Development
Table 81. Enterome BioScience Company Details
Table 82. Enterome BioScience Business Overview
Table 83. Enterome BioScience Microbiome Therapeutics Product
Table 84. Enterome BioScience Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 85. Enterome BioScience Recent Development
Table 86. 4D Pharma Company Details
Table 87. 4D Pharma Business Overview
Table 88. 4D Pharma Microbiome Therapeutics Product
Table 89. 4D Pharma Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 90. 4D Pharma Recent Development
Table 91. Second Genome Company Details
Table 92. Second Genome Business Overview
Table 93. Second Genome Microbiome Therapeutics Product
Table 94. Second Genome Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 95. Second Genome Recent Development
Table 96. AOBiome Company Details
Table 97. AOBiome Business Overview
Table 98. AOBiome Microbiome Therapeutics Product
Table 99. AOBiome Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 100. AOBiome Recent Development
Table 101. C3 Jian Company Details
Table 102. C3 Jian Business Overview
Table 103. C3 Jian Microbiome Therapeutics Product
Table 104. C3 Jian Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 105. C3 Jian Recent Development
Table 106. Rebiotix Company Details
Table 107. Rebiotix Business Overview
Table 108. Rebiotix Microbiome Therapeutics Product
Table 109. Rebiotix Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 110. Rebiotix Recent Development
Table 111. MicroBiome Therapeutics LLC Company Details
Table 112. MicroBiome Therapeutics LLC Business Overview
Table 113. MicroBiome Therapeutics LLC Microbiome Therapeutics Product
Table 114. MicroBiome Therapeutics LLC Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 115. MicroBiome Therapeutics LLC Recent Development
Table 116. Metabiomics Company Details
Table 117. Metabiomics Business Overview
Table 118. Metabiomics Microbiome Therapeutics Product
Table 119. Metabiomics Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 120. Metabiomics Recent Development
Table 121. Ritter Pharmaceuticals Company Details
Table 122. Ritter Pharmaceuticals Business Overview
Table 123. Ritter Pharmaceuticals Microbiome Therapeutics Product
Table 124. Ritter Pharmaceuticals Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 125. Ritter Pharmaceuticals Recent Development
Table 126. Symberix Company Details
Table 127. Symberix Business Overview
Table 128. Symberix Microbiome Therapeutics Product
Table 129. Symberix Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 130. Symberix Recent Development
Table 131. OpenBiome Company Details
Table 132. OpenBiome Business Overview
Table 133. OpenBiome Microbiome Therapeutics Product
Table 134. OpenBiome Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 135. OpenBiome Recent Development
Table 136. Azitra Company Details
Table 137. Azitra Business Overview
Table 138. Azitra Microbiome Therapeutics Product
Table 139. Azitra Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 140. Azitra Recent Development
Table 141. Symbiotix Biotherapies Company Details
Table 142. Symbiotix Biotherapies Business Overview
Table 143. Symbiotix Biotherapies Microbiome Therapeutics Product
Table 144. Symbiotix Biotherapies Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 145. Symbiotix Biotherapies Recent Development
Table 146. Osel Company Details
Table 147. Osel Business Overview
Table 148. Osel Microbiome Therapeutics Product
Table 149. Osel Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 150. Osel Recent Development
Table 151. Metabogen Company Details
Table 152. Metabogen Business Overview
Table 153. Metabogen Microbiome Therapeutics Product
Table 154. Metabogen Revenue in Microbiome Therapeutics Business (2020-2025) & (US$ Million)
Table 155. Metabogen Recent Development
Table 156. Microbiome Therapeutics Market Trends
Table 157. Microbiome Therapeutics Market Drivers
Table 158. Microbiome Therapeutics Market Challenges
Table 159. Microbiome Therapeutics Market Restraints
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
List of Figures
Figure 1. Microbiome Therapeutics Product Picture
Figure 2. Global Microbiome Therapeutics Market Share by Type: 2024 VS 2031
Figure 3. Upper GIT Features
Figure 4. Lower GIT Features
Figure 5. Global Microbiome Therapeutics Market Share by Application: 2024 VS 2031
Figure 6. C. difficile Infection (CDI)
Figure 7. Inflammatory Bowel Disease (IBD)
Figure 8. Orphan Drug
Figure 9. Immuno-oncology
Figure 10. Others
Figure 11. Microbiome Therapeutics Report Years Considered
Figure 12. Global Microbiome Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Microbiome Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Microbiome Therapeutics Revenue Market Share by Region: 2020 VS 2024
Figure 15. North America Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Europe Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. China Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. Japan Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 19. Southeast Asia Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. India Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 21. Central & South America Microbiome Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. Global Microbiome Therapeutics Market Share by Players in 2024
Figure 23. Global Top Microbiome Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Therapeutics as of 2024)
Figure 24. The Top 10 and 5 Players Market Share by Microbiome Therapeutics Revenue in 2024
Figure 25. North America Microbiome Therapeutics Market Share by Type (2020-2025)
Figure 26. North America Microbiome Therapeutics Market Share by Application (2020-2025)
Figure 27. Europe Microbiome Therapeutics Market Share by Type (2020-2025)
Figure 28. Europe Microbiome Therapeutics Market Share by Application (2020-2025)
Figure 29. China Microbiome Therapeutics Market Share by Type (2020-2025)
Figure 30. China Microbiome Therapeutics Market Share by Application (2020-2025)
Figure 31. Japan Microbiome Therapeutics Market Share by Type (2020-2025)
Figure 32. Japan Microbiome Therapeutics Market Share by Application (2020-2025)
Figure 33. Southeast Asia Microbiome Therapeutics Market Share by Type (2020-2025)
Figure 34. Southeast Asia Microbiome Therapeutics Market Share by Application (2020-2025)
Figure 35. India Microbiome Therapeutics Market Share by Type (2020-2025)
Figure 36. India Microbiome Therapeutics Market Share by Application (2020-2025)
Figure 37. Seres Therapeutics Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 38. Assembly Biosciences Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 39. Synthetic Biologics Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 40. Interxon Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 41. PureTech Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 42. Synlogic Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 43. Enterome BioScience Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 44. 4D Pharma Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 45. Second Genome Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 46. AOBiome Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 47. C3 Jian Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 48. Rebiotix Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 49. MicroBiome Therapeutics LLC Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 50. Metabiomics Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 51. Ritter Pharmaceuticals Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 52. Symberix Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 53. OpenBiome Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 54. Azitra Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 55. Symbiotix Biotherapies Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 56. Osel Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 57. Metabogen Revenue Growth Rate in Microbiome Therapeutics Business (2020-2025)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232